Coexisting with Clonal Evolution and BCR-ABL Mutant in CML Patients Treated with Second-generation Tyrosine Kinase Inhibitors Predict the Discrepancy of in vitro Drug Sensitivity
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose :Second-generation tyrosine kinase inhibitors (second TKIs) such as nilotinib and dasatinib control the activity of most ABL kinase domain mutations observed in patients with imatinib resistance. Although in vitro data show that both agents can inhibit all mutations except T315I, some discrepancies have been observed in a small subset of mutation clones. Cytogenetic clonal evolution is the important resistance mechanism of chronic myeloid leukemia (CML). Accordingly, we observed the clinical significance of coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second TKIs. Materials and Methods :We monitored BCR-ABL transcript kinetics, interrelationship of clones expressing nonmutated and mutant transcripts and clonal aberrations within Philadelphia (Ph) positive and negative clones, respectively, in eight patients with CML receiving dasatinib or nilotinib for 3 ∼41 months. Results :Clinical responses were correlated with in vitro sensitivity of the BCR-ABL mutants to the second TKIs in four patients. Four patients showed resistance to the second TKIs as compared to in vitro observations; three of them developed chromosomal abnormalities in the Ph chromosome positive or negative metaphases. Another patient lost the original mutation but acquired a more resistant new mutation and became resistant to the second TKI. Conclusion :Cytogenetic clonal evolution is an independent poor prognostic factor in CML, which could explain the onset of mechanisms for second TKIs resistance to ABL kinase domain mutations. The results indicate that an additional evaluation of chromosomal abnormalities is warranted when BCR-ABL mutants are more resistant than indicated by in vitro data.
Abstract
Purpose :Second-generation tyrosine kinase inhibitors (second TKIs) such as nilotinib and dasatinib control the activity of most ABL kinase domain mutations observed in patients with imatinib resistance. Although in vitro data show that both agents can inhibit all mutations except T315I, some discrepancies have been observed in a small subset of mutation clones. Cytogenetic clonal evolution is the important resistance mechanism of chronic myeloid leukemia (CML). Accordingly, we observed the clinical significance of coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second TKIs. Materials and Methods :We monitored BCR-ABL transcript kinetics, interrelationship of clones expressing nonmutated and mutant transcripts and clonal aberrations within Philadelphia (Ph) positive and negative clones, respectively, in eight patients with CML receiving dasatinib or nilotinib for 3 ∼41 months. Results :Clinical responses were correlated with in vitro sensitivity of the BCR-ABL mutants to the second TKIs in four patients. Four patients showed resistance to the second TKIs as compared to in vitro observations; three of them developed chromosomal abnormalities in the Ph chromosome positive or negative metaphases. Another patient lost the original mutation but acquired a more resistant new mutation and became resistant to the second TKI. Conclusion :Cytogenetic clonal evolution is an independent poor prognostic factor in CML, which could explain the onset of mechanisms for second TKIs resistance to ABL kinase domain mutations. The results indicate that an additional evaluation of chromosomal abnormalities is warranted when BCR-ABL mutants are more resistant than indicated by in vitro data.
참고문헌 (21)
- Sawyers CL, "Chronic myeloid leukemia", N Engl J Med, 340, pp.1330~1340 (1999)
- Kantarjian H, "Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia", N Engl J Med, 346, pp.645~652 (2002)
- Hochhaus A, "Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance", Leukemia, 18, pp.1321~1331 (2004)
- Shah NP, "Multiple BCRABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia", Cancer Cell, 2, pp.117~125 (2002)
- Hochhaus A, "Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy", Leukemia, 16, pp.2190~2196 (2002)
- Quintas-Cardama A, "Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure", Blood, 109, pp.497~499 (2007)
- Jarkowski A, "Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia", Pharmacotherapy, 28, pp.1374~1382 (2008)
- Redaelli S, "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR", ABL mutants, 2009, pp.27, 469~471
- Khorashad JS, "The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib", Leukemia, 20, pp.658~663 (2006)
- Nicolini FE, "Michallet M, Magaud JP, Hayette S. BCR-ABL mutant kinetics in CML patients treated with dasatinib", Leuk Res, 31, pp.865~868 (2007)
- O'Hare T, "Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia", Blood, 110, pp.2242~2249 (2007)
- Khorashad JS, "In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib", Blood, 111, pp.2378~2381 (2008)
- Verma D, "Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia", Am J Hematol, 84, pp.256~257 (2009)
- Polakova KM, "BCR-ABL mutations in chronic myeloid leukemia - not only detection", Leuk Lymphoma, 49, pp.1620~1622 (2008)
- Cortes JE, "Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy", Blood, 101, pp.3794~3800 (2003)
- Saglio G, "Rege-Cambrin G. New therapeutic approaches and prognostic factors in chronic myeloid leukemia", Leuk Lymphoma, 49, pp.625~628 (2008)
- Fabarius A, "Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure", Haematologica, 92, pp.834~837 (2007)
- Jabbour E, "Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase", Blood, 110, pp.2991~2995 (2007)
- Bacher U, "Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha", Leukemia, 19, pp.460~463 (2005)
- Terre C, "Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia", Leukemia, 18, pp.1340~1346 (2004)
- Meeus P, "Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib", Leukemia, 17, pp.465~467 (2003)